A Patient-based Digital Tool to Detect Early Signs of Changes in MS Symptoms and Progression: Your MS Questionnaire

Tjalf Ziemssen¹, Enrique Alvarez², Virender Bhan³, Jason Burton⁴, Olaf Hoffmann⁵, Celia Oreja-Guevara⁶, René Robles-Cedeño⁷, Maria Trojano⁸, Patrick Vermersch⁹, Salvatore Napoli¹⁰, Augusto Miravalle¹¹, Yan Xu¹², Jo Vandercappellen¹³, Mudeer Khwaja¹³, Mark Marchaterre¹⁴, Bianca Stadler¹⁵, Thomas Hach¹³, Gavin Giovannoni¹⁶

¹Department of Neurology, University of British Columbia, Vancouver, BC, Canada; ⁴Centre for Neurological Disorders, Western Australian Neurological Disorders, Western Australia, Perth, Australia; ⁵Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA; ³University of Colorado School of Medicine, Aurora, CO, USA; ³University of School of Medicine, Aurora, CO, USA; ³University of Colorado School of Medicine, Aurora, CO, USA; ³ Alexianer St. Josefs Hospital, Potsdam, Germany; ⁶Multiple Sclerosis Center at the University of Bari, Bari, Italy; ⁹Univ. Lille, FHU Precise, Lille, France; ¹⁰Partners, Multiple Sclerosis Center, and Center for Neurological Imaging, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ¹¹Department of Neurology, University of Colorado, Denver, CO, USA; ¹²Multiple Sclerosis Center, Department of Neurology, Peking Union Medical Sciences, Beijing, China; ¹³Novartis Pharma AG, Basel, Switzerland; ¹⁴Novartis Services Inc., East Hanover, NJ, USA; ¹⁵Novartis Pharma GmbH, Nürnberg, Germany; ¹⁶Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Introduction

PWHY ?	There is an unmet need as discussion of symptoms between people living with multiple sclerosis (plwMS) and healthcare professionals (HCPs) can be unstructured and lead to uncertainty in recognising subtle worsening of (MS) ¹	
O HOW?	Your MS Questionnaire (YMSQ; <u>www.yourms.com</u>) was developed with input from plwMS, patient advocacy groups and HCPs, and is based on the MSProDiscuss™– a physician-completed digital tool (<u>www.msprodiscuss.com</u>) ^{2,3}	
WHAT?	YMSQ is a patient-completed questionnaire that asks for information on relapses, symptoms and impacts experienced within the past 6 months. The purpose of this questionnaire is to facilitate a discussion between HCPs and plwMS to better understand patient history, symptoms and impacts experienced by the patient	• Fig

Objectives


- To develop a patient-based tool, Your MS Questionnaire (YMSQ), that is completed by plwMS
- To evaluate the usability of YMSQ in helping both plwMS and HCPs in clinical practice, and to understand whether the plwMS have experienced any changes in their disease

Methods

Development of YMSQ

- YMSQ was designed based on MSProDiscuss[™] to capture the experience of plwMS regarding changes in their MS symptoms and their impact on daily living over the past 6 months
- The questions were identified as relevant through qualitative and quantitative research with experienced HCPs and using inputs from plwMS and patient organisations
- YMSQ was initially developed as a paper version; however, due to the COVID-19 pandemic and to support telemedicine, plwMS were provided with the option to complete an online or paper version prior to the consultation (**Figure 1**)

Figure 1. Development of YMSQ



HCP, healthcare professional; MS, multiple sclerosis; PAG, patient advisory group; PDF, Portable Document Format; plwMS, people living with MS; US, United States; YMSQ, Your MS Questionnaire

YMSQ usability testing: A two-part HCP survey (Figure 2)


Individual questionnaire (15 questions):

After every patient consultation, feedback was collected for usability and usefulness, comprehensibility, patient and HCP satisfaction and usability in conjunction with MSProDiscuss™

Final questionnaire (15 questions):

- After 40 patient consultations (a minimum of 10), in-depth feedback was collected on usefulness, integration into clinical routine and recommendations for improvement areas
- HCPs had the option to provide their response with one of four categories: strongly agree, agree, disagree, strongly disagree


igure 2. YMSQ usability testing




HCP, healthcare professional; MS, multiple sclerosis; YMSQ, Your MS Questionnaire

Results

- Usability testing of YMSQ is ongoing with HCPs across eight countries. Up to the data cut-off for the interim analysis (12 February 2021), nine HCPs from four countries (US, China, Spain and Italy) completed the testing based on 168 MS patient consultations where YMSQ was used
- Distribution channels for YMSQ, completion status of YMSQ and patient distribution according to YMSQ are presented in Figure 3





*'Mostly' refers to >50% of the questionnaire, while 'Partly' refers to <50% of the questionnaire. MS, multiple sclerosis; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS; YMSQ, Your MS Questionnaire

Figure 4. HCPs' feedback based on the 168 individual questionnaires

Use YMSQ again with this patient 100% Useful for consultation with my patient 99.4% Time to complete YMSQ was satisfactory 97.6% My patient understood the language used 97.6% It was easy for my patient to complete 97% YMSQ

HCP, healthcare professional; MS, multiple sclerosis; YMSQ, Your MS Questionnaire

Figure 3A. Distribution channels for YMSQ, 3B. Completion status of YMSQ^{*}, 3C. Patient distribution in completed YMSQ

• The majority of HCPs agreed or strongly agreed that YMSQ was useful in their practice and was easy for plwMS to use and understand (Figure 4)

• The use of YMSQ positively influenced the clinical practice; it was helpful in engaging patients with their MS

• The majority of HCPs (80%) were willing to integrate YMSQ in addition to MSProDiscuss[™] in routine clinical practice

> Data represent the responses falling under the categories 'strongly agree' and 'agree'

Conclusions

- tool

References

Acknowledgements

The study was funded by Novartis Pharma AG, Basel, Switzerland. Medical writing support was provided by Gillipsie Minhas and Jitendriya Mishra, both of Novartis Healthcare Pvt. Ltd., Hyderabad, India. The final responsibility for the content lies with the authors.

Disclosures

TZ has received compensation for consulting and lecturing from Alexion, Biogen, Celgene, Novartis, Roche, Sanofi, and Teva and for research from Biogen, Novartis, Roche, Teva, and Sanofi. EA received compensation for consulting from Actelion/Janssen, Alexion, Bayer, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Genzyme, Novartis, Sanofi, and TG Therapeutics, and for research from Biogen, Genentech/Roche, Novartis, TG Therapeutics, Patient-Centered Outcomes Research Initiative, National Multiple Sclerosis Society, National Institutes of Health, and Rocky Mountain MS Center. VB received compensation for consulting, lecturing and advisory boards from Biogen, Celgene, EMD Serono, Genzyme, Novartis, Roche, Sanofi, and Teva Neuroscience, and for site PI from Biogen Idec, EMD Serono, Novartis, Sanofi-Aventis, and Teva Neuroscience. **JB** received compensation as a speaker and advisory board member from Bayer Schering, Biogen-Idec, Novartis, Merck Serono, and Sanofi-Genzyme. OH received consulting fees from Biogen, Merck, Novartis, Roche, and Sanofi; compensation for research from Biogen, Novartis, and Sanofi; and as a speaker from Merck, Novartis, Roche, and Sanofi. COG received consulting fees from Novartis Alexion, and Roche; compensation for research from Alexion; and as a speaker from Novartis and Roche. **RRC** has received compensation for consulting services and speaking fees from Biogen, Roche, Novartis, Bayer, Merck, Sanofi, Genzyme, Teva Pharmaceutical Industries Ltd, and Almirall. MT has received compensation for consulting from Novartis, Biogen, Merck, Roche, and Sanofi, and for research and as salary from Biogen, Merck, Novartis, Roche. PV received compensation for consulting and/or research and registration, travel, and accommodation for meetings from Biogen, Roche, Novartis, Sanofi, Teva, Merck, Celgene, Imcyse, and AB Science. SN received compensation as a speaker from Accorda Therapeutics, Biogen, Genentech, Genzyme, Mallinckrodt, and Novartis. AM received compensation for consulting from Novartis, Genentech, Biogen, Alexion, EMD Serono and BMS; for research from Alexion, Novartis, and Biogen; and as a speaker from Alexion, EMD Serono, BMS, and Genentech. YX has nothing to disclose. JV, MK, MM, BS, and TH are employees of Novartis. GG received consulting fees from AbbVie, Actelion, Atara Bio, Biogen, Celgene, Sanofi-Genzyme, Genentech, GlaxoSmithKline, Merck-Serono, Novartis, Roche, and Teva, and compensation for research from Biogen, Roche, Merck, Merck-Serono, Novartis, Sanofi-Genzyme, and Takeda. The data was presented at the Virtual Annual Congress of the American Academy of Neurology, April 17-22, 2021

Copyright © 2021 Novartis Pharma AG. All rights reserved.

Visit the web at: https://www.medcommshydhosting.com/MSKnowledgecenter/

Copies of this poster obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors

Presenter email address: Tjalf.Ziemssen@uniklinikum-dresden.de

• YMSQ was developed with input from plwMS, patient advocacy groups and HCPs, based on the MSProDiscuss[™], a physician-completed digital

• YMSQ facilitates a discussion between plwMS and HCPs on changes in MS symptoms and ways in which they impact daily activities within the past 6 months, enabling a holistic approach to MS patient management

• Based on the initial results from the usability testing of YMSQ in real-world clinical practice, HCPs found it useful and are willing to use it again with the same patients

• When completed before consultations, YMSQ may benefit plwMS and HCPs by enabling a better-structured conversation and a better-informed consultation, with practical uses in telemedicine

Your MS Questionnaire is freely available online at www.yourms.com

1. Davies F et al. Int J MS Care. 2016;18(5):257-264 2. Tollev C et al. JMIR Med Inform. 2020;8(4):e17592. 3. Ziemssen T et al. J Med Internet Res. 2020;22(2):e16932

Poster presented at the 7th Congress of the European Academy of Neurology, June 19-22, 2021



Scan this QR code to download a copy of this poster